{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:02:51Z","timestamp":1772996571281,"version":"3.50.1"},"reference-count":10,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["biomedica"],"abstract":"<jats:p>Introducci\u00f3n. Se han descrito m\u00faltiples efectos adversos con el uso de la terapia biol\u00f3gica para enfermedades autoinmunitarias, muchos de ellos secundarios al estado de inmunosupresi\u00f3n, como las infecciones bacterianas, f\u00fangicas o virales.Caso cl\u00ednico. Se presenta el caso de una mujer de 64 a\u00f1os con diagn\u00f3stico comprobado de criptococosis diseminada secundaria al uso de tofacitinib. Se descartaron otras causas de inmunosupresi\u00f3n, como infecci\u00f3n por el virus de la inmunodeficiencia humana (HIV). Tres a\u00f1os antes se le hab\u00eda diagnosticado artritis reumatoide y se encontraba en tratamiento farmacol\u00f3gico con un agente biol\u00f3gico que inhibe las enzimas JAK. Se han descrito muy pocos casos de criptococosis pulmonar y men\u00edngea en este tipo de pacientes. Conclusi\u00f3n. Este reporte de caso es \u00fatil para que otros m\u00e9dicos tratantes tengan presente la posibilidad de este tipo de infecci\u00f3n f\u00fangica invasora asociada con la terapia biol\u00f3gica y el enfoque de gesti\u00f3n de riesgo.<\/jats:p>","DOI":"10.7705\/biomedica.6239","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T17:01:11Z","timestamp":1657731671000},"page":"218-223","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Criptococosis diseminada por terapia biol\u00f3gica, se debe gestionar el riesgo"],"prefix":"10.7705","volume":"42","author":[{"given":"Efra\u00edn Guillermo","family":"S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1136-848X","authenticated-orcid":false,"given":"Julio","family":"Garc\u00eda-Casallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4444","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"108820","doi-asserted-by":"crossref","unstructured":"Dhillon S. Tofacitinib: A review in rheumatoid arthritis. Drugs. 2017;77:1987-2001. https:\/\/doi.org\/10.1007\/s40265-017-0835-9","DOI":"10.1007\/s40265-017-0835-9"},{"key":"108821","doi-asserted-by":"crossref","unstructured":"Maziarz EK. Cryptococcosis. Infect Dis Clin North Am. 2016;30:179-206. https:\/\/doi.org\/10.1016\/j.idc.2015.10.004","DOI":"10.1016\/j.idc.2015.10.006"},{"key":"108822","doi-asserted-by":"crossref","unstructured":"Molloy SF, Chiller T, Greene GS, Burry J, Govender NP, Kanyama C, et al. Cryptococcal meningitis: A neglected NTD? PLoS Negl Trop Dis. 2017;11:e0005575. https:\/\/doi.org\/10.1371\/JOURNAL.PNTD.0005575","DOI":"10.1371\/journal.pntd.0005575"},{"key":"108823","doi-asserted-by":"crossref","unstructured":"Cada D, Demaris K, Levien T, Baker D. Tofacitinib. Hospital Pharmacy. 2013;48:413-24. https:\/\/doi.org\/10.1310\/hpj4805-413","DOI":"10.1310\/hpj4805-413"},{"key":"108824","doi-asserted-by":"crossref","unstructured":"Sandborn WJ. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-36. https:\/\/doi.org\/10.1056\/nejmoa1606910","DOI":"10.1056\/NEJMoa1606910"},{"key":"108825","doi-asserted-by":"crossref","unstructured":"Zhang Z, Deng W, Wu Q, Sun L. Tuberculosis, hepatitis B and herpes zoster in tofacitinibtreated patients with rheumatoid arthritis. Immunotherapy. 2019;11:321-33.","DOI":"10.2217\/imt-2018-0113"},{"key":"108826","doi-asserted-by":"crossref","unstructured":"Winthrop KL, Park SH, Gul A, Cardiel MH, G\u00f3mez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133-8. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207319","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"108827","unstructured":"Seminario-Vidal L, Cantrell W, Elewski BE. Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis. J Drugs Dermatol. 2015;14:901-2."},{"key":"108828","doi-asserted-by":"crossref","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis. Ann Intern Med. 2013;159:253-26. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00006","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"108829","doi-asserted-by":"crossref","unstructured":"Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14:719-30. https:\/\/doi.org\/10.1080\/1744666X.2018.1512404","DOI":"10.1080\/1744666X.2018.1512404"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/6239\/5048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/6239\/5048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T20:21:23Z","timestamp":1660249283000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/6239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.6239","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"2022-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Presentaci\u00f3n de caso","name":"content_type","label":"Content Type"}]}}